NCT02133664View on ClinicalTrials.gov

Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Multiple SclerosisCognition
Interventions
DRUG

lipoic acid and omega-3 fatty acids

alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid

DRUG

Placebo

placebo lipoic acid and placebo oil

Trial Locations (1)

97239

Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

National Multiple Sclerosis Society

OTHER

lead

Oregon Health and Science University

OTHER

NCT02133664 - Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis | Biotech Hunter | Biotech Hunter